Hurteau J A, Woolas R P, Jacobs I J, Oram D C, Kurman C C, Rubin L A, Nelson D L, Berchuck A, Bast R C, Mills G B
Division of Oncology Research, Toronto General Hospital, Ontario, Canada.
Cancer. 1995 Nov 1;76(9):1615-20. doi: 10.1002/1097-0142(19951101)76:9<1615::aid-cncr2820760918>3.0.co;2-g.
Previous studies have established that soluble interleukin-2 receptor alpha (sIL-2R alpha) levels are elevated in ascites and sera from individuals with advanced ovarian cancer (International Federation of Gynecology and Obstetrics [FIGO] Stage III/IV). This study was undertaken to evaluate sIL-2R alpha levels in individuals with benign ovarian neoplasms and early stage ovarian cancer (FIGO Stage I/II). Comparison with CA 125 levels was performed to assess screening potential.
Sera from 92 healthy individuals, 61 with benign adnexal masses, 12 patients with FIGO Stage I/II ovarian cancers, and 27 patients with FIGO Stage III/IV ovarian cancers were assayed for sIL-2R alpha by enzyme-linked immunosorbent assay and CA 125 by radioimmunoassay.
The mean serum sIL-2R alpha levels for benign pelvic masses, and Stage I/II and Stage III/IV epithelial ovarian cancer were 1507 +/- 82, 1631 +/- 274, and 2596 +/- 384 U/ml, respectively. The difference between mean serum sIL-2R alpha levels in individuals with benign adnexal masses and Stage III/IV epithelial ovarian cancer was statistically significant (P < 0.05). In addition, of the four individuals with FIGO Stage I/II ovarian cancer who had CA125 levels below 35 U/ml, the accepted upper limit of normal, three patients had elevated serum sIL-2R alpha levels. Eleven of 12 patients (92%) with potentially curable Stage I/II disease had elevated serum levels of either sIL-2R alpha or CA125 and 8 of 12 (67%) had elevations of both sIL-2R alpha and CA125. Sensitivity and specificity of a combination of CA 125 and soluble IL-2R alpha were 88.5% and 27.1%, respectively.
Soluble interleukin-2 receptor alpha levels do not appear to differentiate between benign adnexal lesions and early malignancy; however, measurement of sIL-2R alpha levels in combination with CA125 warrants further evaluation to determine if together they will identify individuals with Stages I and II ovarian cancer.
既往研究表明，晚期卵巢癌（国际妇产科联盟[FIGO] III/IV期）患者腹水中和血清中的可溶性白细胞介素-2受体α（sIL-2Rα）水平升高。本研究旨在评估良性卵巢肿瘤和早期卵巢癌（FIGO I/II期）患者的sIL-2Rα水平。通过与CA 125水平进行比较来评估其筛查潜力。
采用酶联免疫吸附测定法检测92名健康个体、61名患有良性附件包块的患者、12名FIGO I/II期卵巢癌患者及27名FIGO III/IV期卵巢癌患者血清中的sIL-2Rα水平，采用放射免疫测定法检测CA 125水平。
良性盆腔包块、I/II期及III/IV期上皮性卵巢癌患者血清sIL-2Rα水平的均值分别为1507±82、1631±274和2596±384 U/ml。良性附件包块患者与III/IV期上皮性卵巢癌患者血清sIL-2Rα水平均值的差异具有统计学意义（P<0.05）。此外，在CA125水平低于正常上限35 U/ml的4名FIGO I/II期卵巢癌患者中，有3名患者血清sIL-2Rα水平升高。12名具有潜在可治愈性的I/II期疾病患者中有11名（92%）血清sIL-2Rα或CA125水平升高，12名中有8名（67%）sIL-2Rα和CA125水平均升高。CA 125与可溶性IL-2Rα联合检测的敏感性和特异性分别为88.5%和27.1%。
可溶性白细胞介素-2受体α水平似乎无法区分良性附件病变和早期恶性肿瘤；然而，联合检测sIL-2Rα水平和CA125值得进一步评估，以确定二者能否共同识别I期和II期卵巢癌患者。
